Strategy Update

16
Dec 2014
0 Comments

A wish for all Canadians

Posted by

By Stacey Johnson, Director of Communications, Centre for Commercialization of Regenerative Medicine

There is much joy and celebration in becoming a centenarian.…

CCRM

By Stacey Johnson, Director of Communications, Centre for Commercialization of Regenerative Medicine

There is much joy and celebration in becoming a centenarian. This March, my grandmother turns 100. If she had one wish, I know it would be for renewed physical vitality. Her mind is strong, but her body is giving out.

Despite huge progress in research, there won’t be a cure for age-related macular degeneration in time for her to benefit, nor will she be able to replace her electronic pacemaker with one made from stem cells, but she’s excited by the promise of stem cell research, even if it won’t impact her directly.

Now is a time for optimism in the regenerative medicine (RM) field, especially in Canada. In October, the Canadian Stem Cell Foundation announced its national Stem Cell Strategy & Action Plan and barely a month later, the Province of Ontario awarded $3.1 million to launch the Ontario Institute for Regenerative Medicine (OIRM).

The regenerative medicine community in Canada is very connected thanks to more than a decade’s worth of targeted encouragement from the federal government – in the form of funding – and efforts by the Canadian Stem Cell Network to break down silos and promote collaboration. With all the key stakeholders working together to develop products and shepherd them through clinical trials to reach patients, the community has research excellence and political will on its side.

The Centre for Commercialization of Regenerative Medicine (CCRM), a unique not-for-profit group that is solely focused on developing and commercializing RM technologies, was involved with both of the recent announcements. The goal of the Stem Cell Strategy & Action Plan is to produce five to 10 therapies within the next 10 years. The OIRM has been established to translate stem cell research into curative therapies for major degenerative diseases. CCRM is the commercialization partner for both groups and is co-leading OIRM with the Ontario Stem Cell Initiative.

With an aging population and Canadian health care costs – direct and indirect – estimated at $190 billion annually, finding treatments and cures is imperative. The Canadian Stem Cell Foundation, OIRM and CCRM will coordinate efforts to move promising stem cell treatments from the bench to the bedside.

My grandmother is unlikely to see cures in her lifetime, but success is feeling closer every day. And that’s something worth celebrating.

Click to read more Close
12
Nov 2014
0 Comments

Dr. Allen Eaves

‘Stem cells will revolutionize medicine’

Posted by

Why the CEO of STEMCELL Technologies supports the Canadian Stem Cell Strategy & Action Plan

While most of us struggle to accomplish one thing in life, Dr.

Why the CEO of STEMCELL Technologies supports the Canadian Stem Cell Strategy & Action Plan

While most of us struggle to accomplish one thing in life, Dr. Allen Eaves has conquered three. A successful research scientist (he advanced the understanding of chronic myelogenous leukemia) and a clinician who made a significant impact on patient care (he founded one of the first and largest bone marrow transplant programs in Canada), Dr. Eaves now runs STEMCELL Technologies, the largest biotech company in British Columbia.

These days, Dr. Eaves sees himself primarily as “a businessman … and a philanthropist.” When he turned 65 in 2006, he had to retire from the University of British Columbia, where he was a professor, and the Vancouver General Hospital, where he had served as Head of Hematology, and from the internationally renowned Terry Fox Lab that he founded in 1981.

“I decided then to move over to STEMCELL and devote myself to growing the company.”

He started his company in 1993, raising the $1 million needed by mortgaging the family home and taking out a Western Economic Diversification loan.  What began as an eight-person operation now employs 600 people, most of whom work in Vancouver, manufacturing high-quality cell and tissue culturing media and tools used by researchers around the world.

“Our tagline is ‘Scientists Helping Scientists’ and that’s very genuine,” says Dr. Eaves.  “If a competitor has a better product, we will tell the scientists they should go with it. But we also feed that information back to our R&D group and come up with an even better product.”

The helpful approach is working: Dr. Eaves expects STEMCELL to hit $100 million in revenues this year. Much of that money will be ploughed back into research and development — the company has a 100-person research department. But Dr. Eaves also invests a significant portion of his profits in stem cell research. He is a major supporter of the Canadian Stem Cell Foundation as both a member of the Board of Directors and a founding Till & McCulloch Leadership Circle member.

Beyond finding treatments for devastating and currently incurable diseases, stem cell-based therapies could help solve the problem of an overloaded health care system, says Dr. Eaves. And he uses the practical example of hip replacements: “Why can’t we figure out how to recoat and fix up arthritic joints so we don’t have to replace them? We should be able to resurface them with stem cell-derived cartilage. That would be simpler and could be done earlier in degenerative arthritis.  And then we wouldn’t have to replace people’s hips.  That’s the sort of practical thing you would like to see happen. That’s what we need to be thinking about.”

He also believes that to succeed in the coming revolution, Canada needs the Stem Cell Strategy & Action Plan, which aligns the scientists doing the research with the industry leaders who can commercialize it and with governments supplying necessary funding to make it happen. “You need the whole spectrum of activities,” he says.

“Stem cell technology is going to revolutionize medicine; that’s the reality. Medicine will be delivered by cells and we will be using cells to repair the body. There is this huge potential out there.”

Click to read more Close
10
Nov 2014
0 Comments

Carlo Fidani,

It makes economic sense

Posted by

Why the CEO of Orlando Corp. believes we need a Canadian Stem Cell Strategy

Supporting health research comes naturally to Carlo Fidani.…

Why the CEO of Orlando Corp. believes we need a Canadian Stem Cell Strategy

Supporting health research comes naturally to Carlo Fidani. It’s in his blood.

“My grandfather was a benevolent man” says Mr. Fidani, Chair and CEO of the Orlando Corporation, one of the oldest and most successful construction and real estate development companies in Canada. “Even in the Depression, when we he didn’t have much, he found ways to help people.”

His father, Orey Fidani, inherited the generosity gene and “felt that investing in health care was something he could do to help the most people.” He passed the character trait along to Carlo, who has taken things to new heights.  In 2011, responding to the shortage of doctors in Ontario, Mr. Fidani contributed $10 million toward the University of Toronto’s Terrence Donnelly Health Sciences Complex to train more students to become MDs. He has also made major donations to advance cancer and mental health research and treatment.

He supports the Canadian Stem Cell Strategy & Action Plan, “because the promise of stem cells is massive.” The man whose company controls more than 40 million square feet of commercial real estate in the Greater Toronto Area sees beyond potential stem cell cures and treatments. He sees the science yielding significant economic dividends.

“The medical aspect of the stem cell is only a part of it. It’s also the economics. If we can reverse the damage of a heart attack, or help someone out who has Parkinson’s or repair a spine, can you imagine what that would do to for the financial model of our health care system?”

Noting that Canada “has always been at the epicentre of stem cell science,” he sees stem cell R&D boosting our economy by creating high-quality jobs. “It’s important from the economics perspective that we continue to find drivers of employment for highly talented people. If we want to consider ourselves a knowledge-based society, this to me is a perfect landing pad for future opportunities.”

To make it all work, though, will mean bringing together the stem cell scientists, the federal and provincial governments and Canadian industry – all pooling their resources and expertise to create and implement the Canadian Stem Cell Strategy.

“It’s no different than running a business. If we have a national strategy we’re going to be far more productive.  Right now the stem cell community is not getting the financial support it needs. In Canada, we can do more with a dollar than virtually any other country in the world.  My sense is that’s why the Strategy is so critical. If we have the ability to do that – if we have the support –  we can produce some particularly spectacular results.”

 

Click to read more Close
30
Oct 2014
0 Comments

Launch of Strategy & Action Plan garners national media attention

Posted by

Wednesday’s launch of the Canadian Stem Cell Strategy & Action Plan made news across the country.  A small sample of the great media coverage the announcement garnered:

  • The Strategy story was the lead Canada item on Global TV.

Strategy Launch Media Conference

Wednesday’s launch of the Canadian Stem Cell Strategy & Action Plan made news across the country.  A small sample of the great media coverage the announcement garnered:

  • The Strategy story was the lead Canada item on Global TV. You can view it here.
  •  It is featured in today’s Globe.
  •  You can also read about it in the PostMedia newspapers.
  • The Canadian Press also circulated the story across Canada. Here’s an example from the Brandon Sun.

The launch was also thoroughly covered in local radio, television and print media outlets.

 

Click to read more Close
29
Oct 2014
0 Comments

Strategy & Action Plan promises major leap forward to alleviate human suffering

Posted by

 

Today is the official launch of the Canadian Stem Cell Strategy & Action Plan to chart  the course for Canada to lead the way in bringing up to 10 breakthrough therapies to the clinic by 2025.…

final press release

 

Today is the official launch of the Canadian Stem Cell Strategy & Action Plan to chart  the course for Canada to lead the way in bringing up to 10 breakthrough therapies to the clinic by 2025.

The 10-year Action Plan outlined in a new report Following Through: Realizing the Promise of Stem Cells – A Canadian Stem Cell Strategy & Action Plan (2015-2025)  was created by scientists, medical professionals, leaders from major health charities, industry experts and philanthropists. It is backed up by an in-depth study by KPMG and has been endorsed by an international panel of experts. The report explains how Canada can transform health care and reduce suffering and death from cardiovascular diseases, cancer, diabetes, vision loss, spinal cord injury and other devastating conditions.

Multiple sclerosis survivor Jennifer Molson was on hand at a press conference on Parliament Hill to support the Action Plan. Molson has been symptom-free for 12 years after receiving a stem cell transplant in a Canadian-led clinical trial. “I’m living proof of the tremendous potential that exists with stem cell research. I got a second chance at life. This Action Plan will help others like me live free of illness and disease.”

“Canada has always been a leader in stem cell research,” said James Price, President and CEO of the Canadian Stem Cell Foundation. “With this Action Plan and the infrastructure already in place, we have the capacity to transform health care in Canada by helping millions of Canadians through new, life-changing therapies and long-term economic growth.”

Dr. Janet Rossant, head of research at SickKids Hospital, said the time is right for Canada to seize the opportunity to move stem cell science forward: “We are at an incredibly exciting time in science where our research is leading to new treatments and therapies.”

“I’m proud to be a part of this historic coalition,” said Dr. Allen Eaves, Founder and CEO of STEMCELL Technologies Inc. “The Action Plan is ready to move forward and already has received private-sector support. Support from all governments will ensure companies like mine are able to create local jobs and, most importantly, transform stem cell research into tangible products and lifesaving therapies.”

Quick facts

  • The Canadian Stem Cell Strategy & Action Plan calls for a $1.5-billion public-private investment over 10 years, including a $50-million average scaled annual commitment by the Government of Canada.
  • The Centre for Commercialization of Regenerative Medicine estimates the Canadian Stem Cell Strategy & Action Plan could generate more than 12,000 jobs for Canadians via the growth of existing companies and the development of new enterprises that reach global markets.
  • In 2013, more than $200 billion was spent on health care in Canada. Two thirds of that money was used to treat incurable diseases. Stem cell research, cell therapy and regenerative medicine are working towards treatment options for these diseases.
Click to read more Close
28
Oct 2014
0 Comments

Cured patient and Canadian stem cell leaders to make major announcement

Posted by

On Wednesday morning, a young woman cured by a stem cell treatment will join with a coalition representing Canadian stem cell researchers, medical professionals, business leaders and health charities for a press conference on Parliament Hill for a major announcement on Parliament Hill about the Canadian Stem Cell Strategy & Action Plan.  …

On Wednesday morning, a young woman cured by a stem cell treatment will join with a coalition representing Canadian stem cell researchers, medical professionals, business leaders and health charities for a press conference on Parliament Hill for a major announcement on Parliament Hill about the Canadian Stem Cell Strategy & Action Plan.  Please revisit this space tomorrow for details.

 

Click to read more Close
12
May 2014
0 Comments

Putting patients first in Strategy

Posted by

Making sure that Canadian patients have safe, early access to the kind of innovative treatments that will emerge from stem cell research was the focus of the Second Health Charities Forum.…

Making sure that Canadian patients have safe, early access to the kind of innovative treatments that will emerge from stem cell research was the focus of the Second Health Charities Forum.

“There clearly is strong support for moving stem cell research forward safely and effectively,” says James Price, President & CEO of the Canadian Stem Cell Foundation, which organized the Forum in partnership with the Health Charities Coalition of Canada.  “The health charities, which represent millions of patients, realize they have an absolutely vital role to play in making sure that patients benefit from the emergence of new stem cell based treatments and cures.”

Held April 29th in Toronto, the second Forum — a first was held in November — was part of an ongoing national dialogue to craft a strategy for advancing stem cell research and development.  Discussion centred on ensuring patients can safely access innovative therapies as they make the transition from clinical trials stage to clinical practice.

The health charities leaders agreed that their organizations are ready to play an important role in patient/public engagement for the Canadian Stem Cell Strategy & Action Plan and its ultimate implementation.

Along with input from the health charities, the final draft of the Strategy,  slated to be ready this fall,  will reflect more than nine months of expert stakeholder consultations with  stem cell researchers, business and community leaders, industry and other leaders.

Second Health Charities Forum Participants

• Bill Barrable (The Rick Hansen Institute)
• Alan Bernstein (Canadian Stem Cell Foundation)
• Sîan Bevan (Canadian Cancer Society)
• Sue DeLisle (Canadian Stem Cell Foundation)
• Sam Donaldson (Ontario Stem Cell Initiative)
• Debbie Fung (KPMG)
• Janet Hux (Canadian Diabetes Association)
• Lori Lyons (The Foundation Fighting Blindness- Canada)
• Robin Markowitz (Lymphoma Canada);
• Michael May (Centre for Commercialization of Regenerative Medicine)
• Rob Oliphant (The Asthma Society)
• Biljana (Billie) Potkonjak (Canadian Liver Foundation)
• James Price (Canadian Stem Cell Foundation)
• Carolyn Pullen (Heart and Stroke Foundation)
• Johnathan Riley (The Arthritis Society)
• Janet Rossant (Ontario Stem Cell Initiative)
• Lisa Salapatek (Crohn’s and Colitis Foundation of Canada)
• Marla Spiegel (Muscular Dystrophy Canada)
• Phil Welford (Stem Cell Network)

Click to read more Close
28
Apr 2014
0 Comments
George Daley Screen Capture

International Panel envisions leading role for Canada in cell therapy boom

Posted by

Canada can play a lead role in the coming boom in regenerative medicine and cell therapy technologies, according to an International Expert Advisory Panel.

Canada can play a lead role in the coming boom in regenerative medicine and cell therapy technologies, according to an International Expert Advisory Panel.

Led by Chair Dr. George Q. Daley of Harvard Medical School, pictured at left, the panelists agreed that stem cell research and development is at a major inflection point, and that the next decade will see the arrival of novel disease treatments that will transform patients’ lives and build a new multibillion dollar cell therapy industry.

The Panel, with experts from stem cell research, ethics, and commercialization and the biomedical industry, met in Toronto earlier this spring to review a draft of the Canadian Stem Cell Strategy & Action Plan.

Panelists agreed that Canada is in a strong position thanks to a remarkable record of research excellence, from the discovery of stem cells more than 50 years ago by Drs. Jim Till and Ernest McCulloch to Dr. John Dick’s identification of the cellular origins of leukemia earlier this year.

The Panel also cited Canada’s collaborative, well-trained and well-equipped R&D community and the country’s universal health care system, which can facilitate large-scale clinical trials, as other key factors in driving new therapies to the clinic.

They saw a clear need for developing and implementing a Canadian strategy to capitalize on those strengths and capture the health and economic benefits that to be realized over the next 10 years.

The International Expert Advisory Panel will meet again in Vancouver in June. The Panel’s comments and suggestions — along with those from workshops with health charities organizations, clinicians, researchers, industry leaders and philanthropists — will help shape the final version of the Strategy.

International Expert Advisory Panel Members

George Q. Daley (Chair)

Samuel E. Lux IV Professor of Hematology/Oncology, Harvard Medical School

Director, Stem Cell Transplantation Program, Children’s Hospital Boston

Boston, MA, USA

Alan Bernstein

President & Chief Executive Officer, Canadian Institute for Advanced Research

Founding President, Canadian Institutes of Health Research

Toronto, ON

Gregory Bonfiglio

Founder & Managing Partner, Proteus Venture Partners

Portola Valley, CA, USA

Julia Levy

Co-Founder and former President & CEO and Chief Scientific Officer, QLT Inc.

Vancouver, BC

Geoff MacKay

President and Chief Executive Officer, Organogenesis Inc.

Canton, MA, USA

Chris Mason

Professor of Regenerative Medicine Bioprocessing

Advanced Centre for Biochemical Engineering, University College of London

London, UK

Debra Mathews

Assistant Director for Science Programs, Berman Institute of Bioethics, Johns Hopkins University

Baltimore, MD, USA

Stephen Minger

Global Head, Research & Development for Cell Technologies, GE Healthcare Life Sciences

London, UK

Martin Pera

Professor Stem Cell Sciences, University of Melbourne

Walter and Eliza Hall Institute and The Florey Neurosciences Institute

Program Leader of Stem Cells Australia

Melbourne, VIC, Australia

Click to read more Close
07
Feb 2014
4 Comments

The doctors are in

Posted by

For a Canadian stem cell strategy to succeed it must make sense to the people who work in the front lines of health care.…

For a Canadian stem cell strategy to succeed it must make sense to the people who work in the front lines of health care. That’s why many of Canada’s most respected medical practitioners gathered in Toronto yesterday to discuss the development of the Canadian Stem Cell Strategy.

The Clinician Forum, which included such notable clinician/researchers as Dr. Hans Messner (who was featured in our recent news article) from Toronto, who pioneered stem cell bone marrow transplants in the early 1970s; Dr. Ivar Mendez, the Unified Head of Surgery of the Province of Saskatchewan, and Dr. Duncan Stewart, CEO and Scientific Director of the Ottawa Hospital Research Institute, was the latest event in a series of national stakeholder consultations. Previous sessions have brought together the country’s top researchers, executives from Canada’s major health charities, biotech leaders and industry experts.

“The clinic is really where the rubber hits the road in terms of health care delivery,” says James Price, President and CEO of the Canadian Stem Cell Foundation, which is championing the Campaign for a Canadian Stem Cell Strategy. “It’s crucial to hear what the clinicians have to say about how to boost clinical trials and speed up the translation of stem cell research to new therapies as quickly and safely as possible..”

Dr. Denis Claude Roy, Scientific Director of Montréal’s Centre de Recherche De L’Hôpital Maisonneuve Rosemont, and a member of the Joint Strategy Working Group, helped organize the forum to discuss the Strategy, which he sees as increasingly important in finding new treatments. “We have learned to harness the potential of stem cells and are now building on these major developments,” says Dr. Roy. “Tissue repair and even cures are now within reach for a multitude of diseases.”

The Clinician Forum, which also included officials from Health Canada who are responsible for the regulatory framework for clinical research, focused on what actions can be taken to advance clinical research and transform stem cell discoveries into improved health outcomes for patients.

The Participants:

François Auger

Director, Laboratoire d’Organogénèse Expérimental, Full Professor, Surgery Department, Faculty of Medicine, Université Laval, Québec, QC

Peter Ganz

Director, Biologics & Genetic Therapies Directorate, Health Canada, Ottawa, ON

Lucie Germain

Scientific Director, Laboratoire d’Organogénèse Expérimental, Professor, Department of Surgery and Associate Professor, Department of Ophthalmology, Faculty of Medicine, Université Laval, Québec, QC

Liz Anne Gillham-Eisen

Acting Director, Office of Policy and International Collaboration, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, ON

Donna Hogge

Senior Scientist, Terry Fox Laboratory, Clinical Professor, Medicine, University of British Columbia, Member, Leukemia Bone Marrow Transplant Program of BC, Vancouver, BC.

Dominique Johnson

Director, Montréal Health Innovations Coordinating Center, a Division of the Montréal Heart Institute, Montréal, QC

Armand Keating

Director, Cell Therapy Program and Philip S. Orsino Facility for Cell Therapy, Princess Margaret Hospital/Ontario Cancer Institute, Senior Scientist, Division of Experimental Therapeutics, Toronto General Research Institute, University Health Network, Director, Division of Hematology, Department of Medicine; Epstein Chair in Cell Therapy and Transplantation, University of Toronto, Toronto, ON

Michael May

Chief Executive Officer, Centre for Commercialization of Regenerative Medicine, Toronto, ON

Jeffrey Medin

Senior Scientist, Ontario Cancer Institute, Senior Scientist, Toronto Western Research Institute, Toronto, ON

Ivar Mendez

Fred H. Wigmore Professor of Surgery, University of Saskatchewan and Unified Head of Surgery for the Province of Saskatchewan, Saskatoon, SK

Hans Messner

Professor of Medicine, University of Toronto, University Health Network, Princess Margaret Hospital, Toronto, ON

Nicolas Noiseux

Cardiac surgeon, Associate Professor of Surgery, Director of Research Cardiovascular Surgery, Hôtel-Dieu du Centre hospitalier de l’université de Montréal, Montréal, QC

James Price

President & Chief Executive Officer, Canadian Stem Cell Foundation, Ottawa, ON

Michael Rosu-Myles

Associate Director, Centre for Biologics Evaluationm, Senior Research Scientist, Stem Cell Research Laboratory, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, ON

Denis Claude Roy

Director, Cellular Therapy Laboratory, Scientific Director, Hôpital Maisonneuve-Rosemont. Professor at the University of Montréal, Montréal, QC

Michael Rudnicki

Senior Scientist and Director of the Regenerative Medicine Program and the Sprott Centre for Stem Cell Research, Ottawa Hospital Research Institute, Professor, Department of Medicine and Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Scientific Director, Stem Cell Network, Ottawa, ON

Khalid Sabihuddin

Program Lead, HUB Health Research Solutions, St. Michael’s Hospital, Toronto, ON

Duncan Stewart

CEO & Scientific Director and Senior Scientist in the Regenerative Medicine Program and Evelyne and Rowell Laishley Chair, Ottawa Hospital Research Institute, Vice-President, Research, The Ottawa Hospital, Professor, Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON

Sowmya Viswanathan

Associate Director Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON

Donna Wall

Professor, Pediatrics and Child Health, Immunology, and Internal Medicine, Pediatric Hematology, Oncology, Transplantation, Director, Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, University of Manitoba. Winnipeg, MB

Philip Welford

Executive Director, Stem Cell Network, Ottawa, ON

Lori West

Professor of Pediatrics, Surgery and Immunology, Director, Canadian National Transplant Research Program, Director (Acting) and Research Director, Alberta Transplant Institute, University of Alberta, Edmonton, AB

David Young

Chair, Ontario Bioscience Innovation Organization, Chief Executive Officer, Actium Research Inc., Toronto, ON

Peter Zandstra

Scientific Director, Centre for Commercialization of Regenerative Medicine, Professor, Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON

Click to read more Close
17
Dec 2013
0 Comments

Industry leaders help plot course

Posted by

What will it take to transform Canadian scientists’ innovative research experiments into stem cell therapies?

A group of industry representatives, from small biotech firms to large multinational health care corporations, met in Toronto on Dec.…

What will it take to transform Canadian scientists’ innovative research experiments into stem cell therapies?

A group of industry representatives, from small biotech firms to large multinational health care corporations, met in Toronto on Dec. 13th to share their insights into how the Canadian Stem Cell Strategy should address this key challenge.

“The information gathered at this first Industry Forum will be crucial in helping to shape the Strategy and finding ways to overcome obstacles that can block excellent research from becoming new treatments and cures,” said James Price, President & CEO of the Canadian Stem Cell Foundation.

The Foundation, in partnership with the Stem Cell Network, the Centre for Commercialization of Regenerative Medicine, the Ontario Stem Cell Initiative and the Health Charities Coalition of Canada is leading the campaign for a Canadian Stem Cell Strategy.

The Industry Forum is one of several consultation sessions underway as part of the process of developing the Strategy. Previous gatherings have included Canada’s major health charities and leading experts in finance and investment. As well, the country’s top scientists are engaged in ongoing discussions to address how to best marshal Canada’s outstanding talent in stem cell research to come up with cures and treatments for currently incurable and untreatable diseases.

Friday’s Forum was followed by a meeting of key members of an International Working Group. The International Group met to give early insight into what other countries are doing and where Canada can have the greatest impact globally.

Industry Forum Participants

Actium Research Inc. 

David Young, Chief Executive Officer

Canadian Stem Cell Foundation

Alan Bernstein,* Chair, Board of Directors

James Price, President & Chief Executive Officer

Centre for Commercialization of Regenerative Medicine

Michael Israels, Chief Operating Officer

Michael May,* Chief Executive Officer

Rahul Sarugaser, Director Business Development

GE Healthcare Life Sciences

Fiona Fitzgerald, National Sales and Marketing Manager

Stephen Minger,* Global Head of Research and Development for Cell Technologies

Insception Biosciences Inc.

Richard Lockie, Chief Executive Officer

Tim Smith, Chief Executive Officer

Proteus Venture Partners

Gregory Bonfiglio,* Founder & Managing Partner

Stem Cell Network

Philip Welford,* Executive Director

Stem Cell Therapeutics

James Parsons, Chief Financial Officer

Tissue Regeneration Therapeutics Inc.

Simon Bubnic, Senior Scientist

University College London

Chris Mason,* Chair, Regenerative Medicine Bioprocessing

* Members of the International Working Group for the Canadian Stem Cell Strategy

Click to read more Close
Back to Top